A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs ABT 767 (Primary)
- Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 20 Oct 2017 Planned End Date changed from 31 Dec 2017 to 15 Dec 2017.
- 21 Jul 2017 Planned End Date changed from 15 Nov 2017 to 31 Dec 2017.
- 22 May 2017 Planned End Date changed from 1 Mar 2017 to 15 Nov 2017.